2021

NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial

NervGen Pharma Corp. Closes Non-Brokered Private Placement

NervGen Pharma Reports Third Quarter 2021 Results

NervGen Pharma Completes $9.2 Million Bought Deal Financing

NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million

NervGen Pharma Announces $5,000,000 Bought Deal Financing

NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 / Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial

NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board

NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile